Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 111171
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111171
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111171
Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens
Si-Jia Li, Yi-Cong Bian, Li-Yan Miao, Chen-Rong Huang, Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
Yi-Xuan Lu, College of Pharmaceutical Science, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
Fang-Yue Zheng, Li-Yan Miao, Chen-Rong Huang, College of Pharmaceutical Science, Soochow University, Suzhou 215000, Jiangsu Province, China
Li-Yan Miao, Chen-Rong Huang, Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou 215006, Jiangsu Province, China
Co-corresponding authors: Li-Yan Miao and Chen-Rong Huang.
Author contributions: Li SJ, Miao LY, and Huang CR designed the research study; Li SJ, Lu YX, Zheng FY, Bian YC, Miao LY, and Huang CR performed the research; Li SJ, Lu YX, and Zheng FY analyzed the data and wrote the manuscript. All authors have read and approve the final manuscript. Miao LY and Chen-Rong Huang contributed equally to this study and are co-corresponding authors.
Supported by the National Natural Science Foundation of China, No. U24A20765 and No. T2321005; Jiangsu Provincial Science and Technology Plan Special Fund, No. BM2023003; Jiangsu Provincial Medical Key Discipline, No. ZDXK202247; the Priority Academic Program Development of the Jiangsu Higher Education Institutes; Jiangsu Engineering Research Center on Drug Evaluation and Translation of Organoids/Organ Chip (2024); the Science and Technology Plan of Suzhou, No. SKYD2023183; the Research Project Established by Chinese Pharmaceutical Association Hospital Pharmacy Department, No. CPA-Z05-ZC-2023002; and Gusu Health Talent Research Project, No. GSWS2022015.
Institutional review board statement: Ethical approval for this study was obtained from the Research Ethics Board of the First Affiliated Hospital of Soochow University (No. 2023178).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chen-Rong Huang, PhD, Department of Pharmacy, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou 215006, Jiangsu Province, China. huangchenrong@suda.edu.cn
Received: June 25, 2025
Revised: August 27, 2025
Accepted: September 28, 2025
Published online: November 15, 2025
Processing time: 142 Days and 20.3 Hours
Revised: August 27, 2025
Accepted: September 28, 2025
Published online: November 15, 2025
Processing time: 142 Days and 20.3 Hours
Core Tip
Core Tip: In this study, retrospectively evaluated the clinical application of adenosine triphosphate-based tumour chemotherapy sensitivity test (ATP-TCA) and revealed that it is an independent prognostic factor for disease-free survival in patients with resectable colorectal cancer. Additionally, an ATP-TCA-sensitive chemotherapy regimen was shown to significantly improve overall survival and disease-free survival in colorectal patients in stage III. Although the necessity for further validation, this study provides evidence supporting the extension of ATP-TCA assays to combination chemotherapy regimens for colorectal cancer while providing a theoretical basis and perspective for future advancements in personalized medicine.